Eli Lilly
3 stories in The Vital Record · Company
-
· Research
AstraZeneca's Oral GLP-1 Pill Trims 11.8% Body Weight in Phase 2 — Phase 3 Now Enrolling -
· Research
In a phase 3 trial, the GLP-1 pill orforglipron cut HbA1c about 1.1 points beyond placebo when added to titrated basal insulin -
· Research
Investigational triple agonist retatrutide lowers HbA1c as diabetes monotherapy in phase 3 trial; up to 15% weight loss was a secondary finding